Physician

Alyssa Ceilesh, D.O.

According to 2025 Medicare claims, Alyssa Ceilesh, D.O. (NPI: 1407273774) practices medical oncology in the Rockford, IL market, with the plurality of this provider's patient population coming from Winnebago, IL. This provider's primary affiliated billing organization is OSF MULTI-SPECIALTY GROUP (NPI: 1922445527; TIN: 383852646) and primary practice location at 61108-2425. Ceilesh is affiliated with the OSF Healthcare System (ACO ID: A3289), participating under the MSSP model.

Ceilesh's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 287 traditional Medicare patients, billed 1,044 HCPCS/CPT codes, and received $91,337 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 977 prescription claims across 178 beneficiaries totaling $2,211,515 in drug costs, led by Xtandi (Enzalutamide). No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs have risen steadily, from $9,210 to $2,211,515. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$46K$91K2021 Medicare payment: $59,803 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $63,419 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $62,284 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $91,337 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018N/RN/RN/R
2019N/RN/RN/R
2020N/RN/RN/R
2021242582$59,803
2022240648$63,419
2023245674$62,284
20242871,044$91,337

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$1.1M$2.2M2015 Drug cost: $9,210 (USD; Tot_Drug_Cst)2016 Drug cost: $34,461 (USD; Tot_Drug_Cst)2017 Drug cost: $6,210 (USD; Tot_Drug_Cst)2018 Drug cost: $535 (USD; Tot_Drug_Cst)2019 Drug cost: $264 (USD; Tot_Drug_Cst)2021 Drug cost: $233,407 (USD; Tot_Drug_Cst)2022 Drug cost: $822,344 (USD; Tot_Drug_Cst)2023 Drug cost: $1,011,554 (USD; Tot_Drug_Cst)2024 Drug cost: $2,211,515 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
201534124$9,210
201640215$34,461
20171995$6,210
2018N/R26$535
2019N/R12$264
2020N/RN/RN/R
202162281$233,407
2022125661$822,344
2023123606$1,011,554
2024178977$2,211,515

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99223Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes4344$133
99215Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more126488$106
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more132222$69
99232Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes58115$61
G2212Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or4567$23

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
XtandiEnzalutamide361,058$506,075
LenalidomideLenalidomide30840$445,640
VerzenioAbemaciclib22616$340,342
EliquisApixaban532,781$44,606
XareltoRivaroxaban452,070$36,157

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

FAQ

What Medicare data is available for Alyssa Ceilesh, D.O.?

Tedicare shows public-source Medicare data for Alyssa Ceilesh, D.O. (NPI 1407273774), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alyssa Ceilesh, D.O. have ACO affiliation data?

Alyssa Ceilesh, D.O. is shown with ACO affiliation data for OSF Healthcare System (MSSP, ACO ID A3289).

What billing organization is linked to Alyssa Ceilesh, D.O.?

Alyssa Ceilesh, D.O. is linked to OSF MULTI-SPECIALTY GROUP (billing NPI 1922445527) in the available physician profile data.

Does Alyssa Ceilesh, D.O. have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.